These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 17971711)

  • 41. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection.
    Hagberg L; Cinque P; Gisslen M; Brew BJ; Spudich S; Bestetti A; Price RW; Fuchs D
    AIDS Res Ther; 2010 Jun; 7():15. PubMed ID: 20525234
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system.
    Martin C; Sönnerborg A; Svensson JO; Ståhle L
    AIDS; 1999 Jul; 13(10):1227-32. PubMed ID: 10416527
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection.
    Suh J; Sinclair E; Peterson J; Lee E; Kyriakides TC; Li FY; Hagberg L; Fuchs D; Price RW; Gisslen M; Spudich S
    J Neuroinflammation; 2014 Dec; 11():199. PubMed ID: 25465205
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection.
    Yilmaz A; Mellgren Å; Fuchs D; Nilsson S; Blennow K; Zetterberg H; Gisslén M
    Infect Dis (Lond); 2019; 51(11-12):838-846. PubMed ID: 31556765
    [No Abstract]   [Full Text] [Related]  

  • 45. Asymmetric dimethylarginine concentrations decrease in patients with HIV infection under antiretroviral therapy.
    Kurz K; Teerlink T; Sarcletti M; Weiss G; Zangerle R; Fuchs D
    Antivir Ther; 2012; 17(6):1021-7. PubMed ID: 22892398
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects.
    Pérez-Valero I; Ellis R; Heaton R; Deutsch R; Franklin D; Clifford DB; Collier A; Gelman B; Marra C; McCutchan JA; Navis A; Sacktor N; Simpson D; Grant I; Letendre S
    AIDS; 2019 Mar; 33(3):475-481. PubMed ID: 30702516
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir.
    Kravcik S; Gallicano K; Roth V; Cassol S; Hawley-Foss N; Badley A; Cameron DW
    J Acquir Immune Defic Syndr; 1999 Aug; 21(5):371-5. PubMed ID: 10458617
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Estimation of virological and immunological parameters in subjects from South India infected with human immunodeficiency virus type 1 clade C and correlation of findings with occurrence of neurological disease.
    Kamat A; Ravi V; Desai A; Satishchandra P; Satish KS; Kumar M
    J Neurovirol; 2009 Jan; 15(1):25-35. PubMed ID: 19031329
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cerebrospinal Fluid Viral Load Across the Spectrum of Untreated Human Immunodeficiency Virus Type 1 (HIV-1) Infection: A Cross-Sectional Multicenter Study.
    Ulfhammer G; Edén A; Antinori A; Brew BJ; Calcagno A; Cinque P; De Zan V; Hagberg L; Lin A; Nilsson S; Oprea C; Pinnetti C; Spudich S; Trunfio M; Winston A; Price RW; Gisslén M
    Clin Infect Dis; 2022 Aug; 75(3):493-502. PubMed ID: 34747481
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression.
    Caby F; Guihot A; Lambert-Niclot S; Guiguet M; Boutolleau D; Agher R; Valantin MA; Tubiana R; Calvez V; Marcelin AG; Carcelain G; Autran B; Costagliola D; Katlama C
    Clin Infect Dis; 2016 May; 62(10):1297-1303. PubMed ID: 26908792
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection.
    Hermansson L; Yilmaz A; Axelsson M; Blennow K; Fuchs D; Hagberg L; Lycke J; Zetterberg H; Gisslén M
    J Neuroinflammation; 2019 Jan; 16(1):16. PubMed ID: 30678707
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative Analysis of Cell-Associated HIV DNA Levels in Cerebrospinal Fluid and Peripheral Blood by Droplet Digital PCR.
    de Oliveira MF; Gianella S; Letendre S; Scheffler K; Kosakovsky Pond SL; Smith DM; Strain M; Ellis RJ
    PLoS One; 2015; 10(10):e0139510. PubMed ID: 26431315
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study.
    Jespersen S; Pedersen KK; Anesten B; Zetterberg H; Fuchs D; Gisslén M; Hagberg L; Trøseid M; Nielsen SD
    BMC Infect Dis; 2016 Apr; 16():176. PubMed ID: 27103116
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients.
    Karlström O; Ståhle L; Perrin L; Tegude H; Sönnerborg A
    Scand J Infect Dis; 2006; 38(5):371-4. PubMed ID: 16709540
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cerebrospinal fluid CXCL10 is associated with the presence of low level CSF HIV during suppressive antiretroviral therapy.
    Anderson AM; Kundu S; Tang B; Vaida F; Okwuegbuna O; McClernon D; Cherner M; Deutsch R; Cookson D; Crescini M; Grant I; Zetterberg H; Blennow K; Gisslen M; Ellis RJ; Letendre SL
    J Neuroimmunol; 2021 Apr; 353():577493. PubMed ID: 33571816
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.
    Spudich SS; Nilsson AC; Lollo ND; Liegler TJ; Petropoulos CJ; Deeks SG; Paxinos EE; Price RW
    BMC Infect Dis; 2005 Nov; 5():98. PubMed ID: 16266436
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV-infected adults on a long-term non-nucleoside reverse transcriptase inhibitor-based regimen.
    Allavena C; Rodallec A; Sécher S; Reliquet V; Baffoin S; André-Garnier E; Billaud E; Raffi F; Ferré V
    J Med Virol; 2013 Nov; 85(11):1878-82. PubMed ID: 23861166
    [TBL] [Abstract][Full Text] [Related]  

  • 59. What can characterization of cerebrospinal fluid escape populations teach us about viral reservoirs in the central nervous system?
    Joseph SB; Trunfio M; Kincer LP; Calcagno A; Price RW
    AIDS; 2019 Dec; 33 Suppl 2():S171-S179. PubMed ID: 31790378
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.
    Mellgren A; Antinori A; Cinque P; Price RW; Eggers C; Hagberg L; Gisslén M
    Antivir Ther; 2005; 10(6):701-7. PubMed ID: 16218168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.